Zentalis Pharmaceuticals (ZNTL) EBIT Margin (2024)
Zentalis Pharmaceuticals' (ZNTL) quarterly EBIT Margin came in at 185.55% in Q4 2024, down 203.9% quarter-over-quarter from 61.06% in Q1 2024.
Zentalis Pharmaceuticals (ZNTL) EBIT Margin (2024) Analysis & Trends
Zentalis Pharmaceuticals' EBIT Margin history runs 1 years deep, the most recent figure standing at 185.55% for Q4 2024.
- On a quarterly basis, EBIT Margin changed N/A year-over-year to 185.55% in Q4 2024; TTM through Sep 2025 was 615.16%, a 9922.0% decrease from a year earlier, with the FY2024 full-year figure at 283.57%, changed N/A from the prior year.
- EBIT Margin declined to 185.55% in Q4 2024 per ZNTL's latest filing, from 61.06% in the prior quarter.
- Across five years, EBIT Margin topped out at 61.06% in Q1 2024 and bottomed at 185.55% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zentalis Pharmaceuticals | 312.67 Mn | 312.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -185.55% |
| Mar 31, 2024 | -61.06% |